Pro-Dex, Inc.

NASDAQ:PDEX

Medical - Instruments & Supplies

Healthcare
$63.94 +5.86%

+$3.54 today

Market cap
$204.61M
Beta
-0.00
P/E (TTM)
17.1
EPS (TTM)
$3.75
52W Low $23.47High $68.99

Volume 0.04M

Average 0.04M

PDEX Debt Repayment

Cash used to repay borrowings during the period.

Pro-Dex, Inc.NASDAQ: PDEX

Debt Repayment · Q3 FY2026 · quarter ended Mar 2026

Debt repayment turns negative

Q3 FY2026 debt repayment was -$593K, compared with $1.9M a year earlier. Trailing-twelve-month debt repayment was -$8.41M. Over 3 fiscal years it compounded at +66.3% a year.

Context

  • Debt repayment amounted to 5.2% of revenue in FY2025, up 3.7 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near -$593K or moves back toward the trailing-twelve-month quarterly average of -$2.1M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$593K-78.6% QoQ
Last fiscal yearJun 2025
$3.48M+525.9% YoY
LTMMar 2026
-$8.41M-228.6% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-131.2%——
1 year+525.9%——
3-year CAGR+66.3%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
3.48M USD
Year-over-year change
+525.9%
4-year CAGR
-20.7%

Debt Repayment vs competitors

How PDEX compares with its peers on the latest reported figures

  • PDEX's LTM Mar 2026 debt repayment of $8.41M is the 2nd largest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of -228.6% is the lowest of 7, against a peer median of -24.4%.
  • Debt repayment amounts to 11.3% of revenue for PDEX, versus a peer median of 27.8%.
PDEX Competitors Peer median
Debt Repayment for PDEX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$19.09M +59756.3%—55.5%
PDEXPro-Dex, Inc.LTM Mar 2026$8.41M -228.6%+66.3%11.3%
STSSSkyAI, Inc.LTM Mar 2026$4.54M +369.3%—1144.9%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$348K -48.7%-36.8%—
SERASera Prognostics, Inc.LTM Mar 2026$81K -81.9%-13.8%142.1%
APYXApyx Medical CorporationLTM Mar 2026$20K +0.0%-48.7%0.0%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$0 ———
LUCDLucid Diagnostics Inc.LTM Mar 2026$0 -100.0%—0.0%
MBOTMicrobot Medical Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding PDEX) $0-24.4%-36.8%27.8%

Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income4.57M4.57M7.07M2.13M8.98M
Depreciation & Amortization726K726K857K1.16M1.24M
Deferred Income Tax(63K)(63K)264K(1.56M)140K
Stock-Based Compensation1.28M1.28M766K605K555K
Change in Working Capital(6.54M)(6.54M)396K(225K)(10.45M)
Accounts Receivables(4.45M)(4.45M)5.43M(3.94M)(2.55M)
Inventory(4.24M)(4.24M)(3.49M)898K(6.94M)
Accounts Payables1.99M1.99M(1.15M)2.44M179K
Other Working Capital162K162K(394K)376K(1.14M)
Other Non-Cash Items(820K)(820K)(3.9M)4.1M(2.14M)
Operating Cash Flow(847K)(847K)5.46M6.2M(1.68M)
Capital Expenditures(1.67M)(1.67M)(974K)(983K)(1.25M)
Acquisitions (Net)00000
Purchases of Investments(334K)(334K)0(1.25M)0
Sales of Investments770K770K89K01.31M
Other Investing Activities(33K)(33K)00(304K)
Investing Cash Flow(1.24M)(1.24M)(885K)(2.23M)(238K)
Debt Repayment8.79M756K(809K)(816K)3.48M
Common Stock Issued96K00042K
Common Stock Repurchased(5.54M)(1.61M)(1.55M)(3.51M)(3.5M)
Dividends Paid00000
Other Financing Activities(4.14M)60K(134K)50K(305K)
Financing Cash Flow(790K)(790K)(2.49M)(4.27M)(292K)
Effect of Forex Changes00000
Net Change in Cash(2.87M)(2.87M)2.09M(305K)(2.21M)
Free Cash Flow(2.52M)(2.52M)4.49M5.22M(2.93M)

Pro-Dex, Inc.

NASDAQ:PDEX

Intrinsic Alpha fair value

Locked

Current Price

$63.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.